Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 12/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | RGS12 | O14924 | 1/20 | 0.38 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.38 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7947717 | 0.81 | SLC29A1 (0.86) | SLC29A1PKMNPC1MAPTLMNA | |
| SCHEMBL7971739 | 0.81 | SLC29A1 (0.60) | SLC29A1MAPTLMNAKDM4ETSHR | |
| SCHEMBL7953158 | 0.80 | SLC29A1 (0.74) | SLC29A1PKMNPC1MAPTLMNA | |
| SCHEMBL7949410 | 0.79 | SLC29A1 (0.63) | SLC29A1PKMNPC1MAPTLMNA | |
| SCHEMBL1276832 | 0.75 | SLC29A1 (0.61) | SLC29A1MAPTLMNAKDM4ETSHR | |
| SCHEMBL9565592 | 0.74 | SLC29A1 (0.49) | SLC29A1PKMNPC1MAPTLMNA | |
| SCHEMBL7970119 | 0.73 | SLC29A1 (0.66) | SLC29A1MAPTLMNAKDM4ETSHR | |
| SCHEMBL11471053 | 0.72 | HTT (0.58) | PKMNPC1MAPTLMNAKDM4E | |
| SCHEMBL7976583 | 0.70 | SLC29A1 (0.71) | SLC29A1MAPTLMNAKDM4ETSHR | |
| SCHEMBL7960351 | 0.70 | SLC29A1 (0.61) | SLC29A1MAPTLMNAKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2001517226-A | — | — | 2001-10-02 | — | — | JP | claimed |
| EP-0971925-A1 | PYRIMIDOPYRIMIDINE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2000-01-19 | — | — | EP | claimed |
| WO-1998043974-A1 | PYRIMIDOPYRIMIDINE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-10-08 | — | — | WO | claimed |
| US-20240166770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CELL-PENETRATING ANTIBODIES | YALE UNIVERSITY | 2024-05-23 | — | — | US | disclosed |
| WO-2021077070-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CELL-PENETRATING ANTIBODIES | YALE UNIVERSITY (US) | 2021-04-22 | — | — | WO | disclosed |
| US-6297250-B1 | USEFUL FOR INHIBITING TRANSPORT OF NUCLEOSIDES OR PURINES ACROSS CELL MEMBRANES, THEREBY TO POTENTIATE THE ACTIVITY OF VARIOUS CYTOTOXIC ANTITUMOR DRUGS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CELL-PENETRATING ANTIBODIES | SLC29A1, SLC29A2, SLC7A1 | SLC29A1 1/4885PKM 1421/4885NPC1 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.